X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3764) 3764
Publication (243) 243
Newsletter (30) 30
Book Review (20) 20
Book Chapter (8) 8
Magazine Article (7) 7
Conference Proceeding (4) 4
Dissertation (4) 4
Newspaper Article (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1990) 1990
animals (1845) 1845
male (1829) 1829
index medicus (1513) 1513
female (1462) 1462
benzoates - administration & dosage (1284) 1284
benzoates - pharmacology (1039) 1039
benzoates - therapeutic use (982) 982
rats (911) 911
pharmacology & pharmacy (690) 690
adult (641) 641
middle aged (617) 617
mice (541) 541
administration, oral (415) 415
benzoates - adverse effects (414) 414
aged (410) 410
time factors (378) 378
telmisartan (377) 377
benzimidazoles - administration & dosage (374) 374
treatment outcome (374) 374
dose-response relationship, drug (373) 373
benzimidazoles - therapeutic use (305) 305
hypertension - drug therapy (277) 277
adolescent (274) 274
rats, sprague-dawley (272) 272
benzoates - pharmacokinetics (269) 269
hypertension (265) 265
hematology (257) 257
blood pressure - drug effects (250) 250
estradiol benzoate (238) 238
benzoic acid (236) 236
benzimidazoles - pharmacology (235) 235
drug therapy, combination (234) 234
sodium benzoate (221) 221
benzoates - chemistry (216) 216
rats, wistar (215) 215
research (213) 213
benzoates (212) 212
child (205) 205
disease models, animal (196) 196
triazoles - administration & dosage (194) 194
triazoles - therapeutic use (189) 189
analysis (188) 188
neurosciences (180) 180
angiotensin ii type 1 receptor blockers - administration & dosage (177) 177
biochemistry & molecular biology (176) 176
iron chelating agents - therapeutic use (176) 176
oncology (174) 174
estradiol - pharmacology (171) 171
deferasirox (169) 169
iron chelating agents - administration & dosage (169) 169
pregnancy (167) 167
benzoates - metabolism (166) 166
pharmacokinetics (164) 164
iron overload - drug therapy (162) 162
angiotensin ii type 1 receptor blockers - therapeutic use (161) 161
double-blind method (160) 160
health aspects (160) 160
expression (158) 158
care and treatment (156) 156
drug combinations (156) 156
peripheral vascular disease (155) 155
drug therapy (150) 150
antihypertensive agents - administration & dosage (144) 144
efficacy (144) 144
oxidative stress (140) 140
young adult (137) 137
estradiol - administration & dosage (135) 135
pyrazoles - therapeutic use (135) 135
child, preschool (134) 134
hydrazines - therapeutic use (134) 134
angiotensin ii type 1 receptor blockers - pharmacology (131) 131
toxicology (131) 131
metabolism (130) 130
safety (130) 130
dosage and administration (125) 125
pyrazoles - administration & dosage (125) 125
antihypertensive agents - therapeutic use (124) 124
endocrinology & metabolism (123) 123
receptors, thrombopoietin - agonists (123) 123
therapy (122) 122
article (120) 120
inflammation (120) 120
medicine, general & internal (118) 118
hydrazines - administration & dosage (117) 117
mice, inbred c57bl (116) 116
rodents (114) 114
benzimidazoles - adverse effects (113) 113
angiotensin-converting enzyme inhibitors - administration & dosage (112) 112
medicine (112) 112
eltrombopag (111) 111
monoterpenes (111) 111
research article (111) 111
liver - metabolism (110) 110
benzoates - blood (109) 109
dogs (109) 109
medicine, research & experimental (108) 108
double-blind (107) 107
purpura, thrombocytopenic, idiopathic - drug therapy (107) 107
drug administration schedule (106) 106
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3457) 3457
German (100) 100
Russian (59) 59
Japanese (51) 51
French (41) 41
Chinese (35) 35
Italian (19) 19
Spanish (16) 16
Polish (8) 8
Czech (5) 5
Danish (4) 4
Hungarian (3) 3
Portuguese (3) 3
Bulgarian (2) 2
Dutch (2) 2
Norwegian (2) 2
Romanian (2) 2
Serbian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Seminars in Oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 635 - 647
Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite... 
TUMOR-NECROSIS-FACTOR | LOW-RISK | COLONY-STIMULATING FACTOR | ONCOLOGY | GM-CSF | RECOMBINANT-HUMAN-ERYTHROPOIETIN | ERYTHROID RESPONSE | TRANS-RETINOIC ACID | QUALITY-OF-LIFE | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Recombinant Proteins - therapeutic use | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Erythropoietin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Erythropoietin - adverse effects | Thrombopoietin - therapeutic use | Recombinant Proteins - adverse effects | Thrombopoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Filgrastim | Patient Selection | Receptors, Fc - therapeutic use | Erythropoietin - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions | Colony-Stimulating Factors - adverse effects | Epoetin Alfa | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Colony-Stimulating Factors - therapeutic use | Pyrazoles - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Erythropoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Hydrazines - therapeutic use | Hematinics - therapeutic use | Polyethylene Glycols | Hematinics - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Hematinics - administration & dosage | Recombinant Proteins - administration & dosage | Benzoates - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Pyrazoles - administration & dosage | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Darbepoetin alfa | Colony-Stimulating Factors - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Hydrazines - adverse effects
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 12/2007, Volume 176, Issue 11, pp. 1138 - 1145
Rationale: Nitric oxide-independent agonists of soluble guanylate cyclase (sGC) have been developed. Objectives: We tested whether inhalation of novel... 
BAY 41-2272 | BAY 58-2667 | Pulmonary hypertension | BAY 41-8543 | Soluble guanylate cyclase | LARGE POROUS PARTICLES | AUGMENTS | pulmonary hypertension | INHALATION | soluble guanylate cyclase | DELIVERY | INHIBITION | ACTIVATOR | RESPIRATORY SYSTEM | BAY-41-2272 | NITRIC-OXIDE | AWAKE LAMBS | HYPERTENSION | CRITICAL CARE MEDICINE | Oxadiazoles - administration & dosage | Injections, Intravenous | Nitric Oxide - pharmacology | Purinones - administration & dosage | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Oxadiazoles - pharmacology | Lung - metabolism | Pyrazoles - pharmacology | Powders | Pyridines - administration & dosage | Quinoxalines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Administration, Inhalation | Morpholines - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Soluble Guanylyl Cyclase | Receptors, Cytoplasmic and Nuclear - agonists | Pyrimidines - pharmacology | Nitric Oxide - administration & dosage | Benzoates - administration & dosage | Particle Size | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Cyclic GMP - metabolism | Guanylate Cyclase | Lung - drug effects | Aerosols | Benzoates - pharmacology | Purinones - pharmacology | Sheep | Pulmonary Circulation - drug effects | Pyridines - pharmacology | Vasodilation - drug effects | Drug Combinations | H. Pulmonary Vascular Disease
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2015, Volume 28, Issue 1, pp. 57 - 69
Journal Article
Journal Article